Skip to main content
Indegene Limited logo

Indegene Limited — Investor Relations & Filings

Ticker · INDGN ISIN · INE065X01017 LEI · 335800XFEREFIW9LG995 BSE.NS Professional, scientific and technical activities
Open in API
Filings indexed 290 across all filing types
Latest filing 2025-03-26 Regulatory Filings
Country IN India
Listing BSE.NS INDGN

About Indegene Limited

https://www.indegene.com/

Indegene Limited provides digital-led commercialization services for the life sciences sector. The company integrates deep domain knowledge with proprietary technology platforms to assist biopharmaceutical, emerging biotech, and medical device organizations. Its core offerings span the entire product lifecycle, including clinical development support, regulatory compliance, pharmacovigilance, and multi-channel marketing operations. By leveraging artificial intelligence and machine learning, Indegene enables clients to optimize drug development processes, enhance patient engagement, and drive operational efficiencies. The company focuses on modernizing traditional commercial models through data-driven insights and digital transformation strategies, helping global healthcare organizations navigate complex regulatory environments and improve health outcomes through scaled, technology-enabled solutions.

Recent filings

Filing Released Lang Actions
General Updates
Regulatory Filings Classification · 95% confidence The document is a letter from Indegene Limited to stock exchanges responding to a warning letter issued by the National Stock Exchange of India regarding a compliance issue related to disclosure of PAN information in filings. The letter states corrective actions taken and requests the information be taken on record. There are no financial statements, earnings data, or detailed report content. The document is short (3321 characters) and primarily serves as a regulatory compliance communication and corrective action notice. It does not contain an actual report or financial data, nor is it a certification letter. This fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance communication.
2025-03-26 English
Acquisition
M&A Activity Classification · 100% confidence The document is a formal disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It announces the approval and details of an acquisition by the company of MJL Communications Group Ltd. and its subsidiary. The content includes specifics about the acquisition such as the target entity, consideration, percentage of shares acquired, and business rationale. There are no financial statements or detailed financial performance data presented, only an announcement of a corporate transaction. This fits the definition of M&A Activity (TAR) filings, which cover announcements and documents related to merger proposals or takeover bids.
2025-03-25 English
Updates
Board/Management Information Classification · 95% confidence The document is a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It reports decisions made by the Board of Directors of Indegene Limited at a meeting held on March 19, 2025. The disclosures include approval of investment in a wholly owned subsidiary, re-appointment and recommendation of secretarial auditors. The document provides detailed information about the investment and auditor appointments, which are typical of board meeting disclosures. There is no financial statement or comprehensive financial report included. The document is an announcement of board decisions and changes related to management and governance, not a full annual or interim report, audit report, or earnings release. Therefore, it fits best under Board/Management Information (MANG). The document length (8853 characters) and content confirm it is not a brief announcement or a report publication announcement but a substantive disclosure of board decisions.
2025-03-19 English
Change in Auditors
Board/Management Information Classification · 95% confidence The document is a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It reports decisions made by the Board of Directors of Indegene Limited at a meeting held on March 19, 2025. The disclosures include approval of investment in a wholly owned subsidiary and appointment/re-appointment of secretarial auditors. The document is an announcement of board decisions and changes related to management and governance, not a full report or financial statement. It does not contain financial statements or detailed financial analysis but rather informs about board approvals and appointments. Therefore, it fits best under Board/Management Information (MANG).
2025-03-19 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the expansion of Indegene's presence in Europe with a new center in London. It is addressed to stock exchanges pursuant to a regulatory disclosure requirement (Regulation 30 of SEBI LODR), but it does not contain financial statements, management discussion, or detailed financial data. The document is relatively short (4163 characters) and serves as an announcement of a corporate development rather than a financial report or detailed filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is also not a regulatory certification or insider dealing report. The best fitting category is Regulatory Filings (RNS), which is a fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2025-03-19 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges informing about the schedule of an upcoming analyst/investor meeting. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, which pertains to disclosure of material events. The content is about notifying the schedule of a meeting, explicitly stating no unpublished price sensitive information will be shared. There are no financial statements, results, or detailed presentations included. The document length is short (1592 characters), and it serves as an announcement rather than a report or transcript. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2025-03-18 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.